Iranian Red Crescent Medical Journal

Published by: Kowsar

Prostate Cancer: Current Treatment and Prevention Strategies

Fang-zhi Chen 1 and Xiao-kun Zhao 1 , *
Authors Information
1 Department of Urology, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China
Article information
  • Iranian Red Crescent Medical Journal: April 5, 2013, 15 (4); 279-284
  • Published Online: April 5, 2013
  • Article Type: Review Article
  • Received: May 24, 2012
  • Accepted: January 22, 2013
  • DOI: 10.5812/ircmj.6499

To Cite: Chen F, Zhao X. Prostate Cancer: Current Treatment and Prevention Strategies, Iran Red Crescent Med J. 2013 ; 15(4):279-284. doi: 10.5812/ircmj.6499.

Copyright © 2013, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Discussion
  • 1. Brinkman M, Reulen RC, Kellen E, Buntinx F, Zeegers MP. Are men with low selenium levels at increased risk of prostate cancer? Eur J Cancer. 2006; 42(15): 2463-71[DOI][PubMed]
  • 2. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13): 1310-9[DOI][PubMed]
  • 3. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360(13): 1320-8[DOI][PubMed]
  • 4. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009; 302(11): 1202-9[DOI][PubMed]
  • 5. Mongiat-Artus P, Peyromaure M, Richaud P, Droz JP, Rainfray M, Jeandel C, et al. [Recommendations for the treatment of prostate cancer in the elderly man: A study by the oncology committee of the French association of urology]. Prog Urol. 2009; 19(11): 810-7[DOI][PubMed]
  • 6. Lawrentschuk N, Trottier G, Kuk C, Zlotta AR. Role of surgery in high-risk localized prostate cancer. Curr Oncol. 2010; 17 Suppl 2-32[PubMed]
  • 7. Donnelly BJ, Saliken JC, Brasher PM, Ernst SD, Rewcastle JC, Lau H, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer. 2010; 116(2): 323-30[DOI][PubMed]
  • 8. Koupparis A, Gleave ME. Multimodal approaches to high-risk prostate cancer. Curr Oncol. 2010; 17 Suppl 2-7[PubMed]
  • 9. Montie JE. Initial therapy with radical prostatectomy for high risk localized prostate cancer. J Urol. 2006; 176(6 Pt 2)-9[DOI][PubMed]
  • 10. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005; 352(19): 1977-84[DOI][PubMed]
  • 11. Palisaar RJ, Noldus J. [The role of surgery in locally advanced prostate cancer]. Urologe A. 2008; 47(11): 1417-23[DOI][PubMed]
  • 12. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol. 2008; 53(1): 68-80[DOI][PubMed]
  • 13. Briganti A, Chun FK, Salonia A, Gallina A, Farina E, Da Pozzo LF, et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int. 2006; 98(4): 788-93[DOI][PubMed]
  • 14. Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, et al. Pelvic lymph node dissection in prostate cancer. Eur Urol. 2009; 55(6): 1251-65[DOI][PubMed]
  • 15. Zorn KC, Katz MH, Bernstein A, Shikanov SA, Brendler CB, Zagaja GP, et al. Pelvic lymphadenectomy during robot-assisted radical prostatectomy: Assessing nodal yield, perioperative outcomes, and complications. Urology. 2009; 74(2): 296-302[DOI][PubMed]
  • 16. Hayden AJ, Catton C, Pickles T. Radiation therapy in prostate cancer: a risk-adapted strategy. Curr Oncol. 2010; 17 Suppl 2-24[PubMed]
  • 17. Law AB, McLaren DB. Non-surgical treatment for early prostate cancer. J R Coll Physicians Edinb. 2010; 40(4): 340-2[DOI][PubMed]
  • 18. Giberti C, Chiono L, Gallo F, Schenone M, Gastaldi E. Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol. 2009; 27(5): 607-12[DOI][PubMed]
  • 19. Buron C, Le Vu B, Cosset JM, Pommier P, Peiffert D, Delannes M, et al. Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study. Int J Radiat Oncol Biol Phys. 2007; 67(3): 812-22[DOI][PubMed]
  • 20. Pinkawa M. External beam radiotherapy for prostate cancer. Panminerva Med. 2010; 52(3): 195-207[PubMed]
  • 21. Levin WP, Kooy H, Loeffler JS, DeLaney TF. Proton beam therapy. Br J Cancer. 2005; 93(8): 849-54[DOI][PubMed]
  • 22. Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995; 32(1): 3-12[DOI][PubMed]
  • 23. Slater JD, Rossi CJ, Jr, Yonemoto LT, Bush DA, Jabola BR, Levy RP, et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys. 2004; 59(2): 348-52[DOI][PubMed]
  • 24. Kagan AR, Schulz RJ. Proton-beam therapy for prostate cancer. Cancer J. 2010; 16(5): 405-9[DOI][PubMed]
  • 25. Tsivian M, Polascik TJ. Focal cryotherapy for prostate cancer. Curr Urol Rep. 2010; 11(3): 147-51[DOI][PubMed]
  • 26. Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology. 2002; 60(2 Suppl 1): 3-11[PubMed]
  • 27. Hubosky SG, Fabrizio MD, Schellhammer PF, Barone BB, Tepera CM, Given RW. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life. J Endourol. 2007; 21(12): 1521-31[DOI][PubMed]
  • 28. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006; 50(5): 935-9[DOI][PubMed]
  • 29. Johnson MT, Lowe GJ, Bahnson RR. Androgen deprivation therapy: a primer on concepts and therapeutic options. J Men's Health. 2010; 7(4): 358-367
  • 30. Kaarbo M, Klokk TI, Saatcioglu F. Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays. 2007; 29(12): 1227-38[DOI][PubMed]
  • 31. Askew EB, Gampe RT, Jr, Stanley TB, Faggart JL, Wilson EM. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem. 2007; 282(35): 25801-16[DOI][PubMed]
  • 32. Ramsay AK, Leung HY. Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy. Clin Sci (Lond). 2009; 117(6): 209-28[DOI][PubMed]
  • 33. Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol. 2007; 9 Suppl 1-8[PubMed]
  • 34. Huggins C, Hodges Cl V. Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate. J Urology. 2002; 168(1): 9-12
  • 35. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009; 302(8): 866-73[DOI][PubMed]
  • 36. Maroni PD, Crawford ED. The benefits of early androgen blockade. Best Pract Res Clin Endocrinol Metab. 2008; 22(2): 317-29[DOI][PubMed]
  • 37. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24(27): 4448-56[DOI][PubMed]
  • 38. Picard JC, Golshayan AR, Marshall DT, Opfermann KJ, Keane TE. The multi-disciplinary management of high-risk prostate cancer. Urol Oncol. 2012; 30(1): 3-15[DOI][PubMed]
  • 39. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15): 1502-12[DOI][PubMed]
  • 40. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008; 26(2): 242-5[DOI][PubMed]
  • 41. Williamson L, Katherine A , Fenton C. Docetaxel. Drugs. 2005; 65(17): 2513-31[DOI]
  • 42. Petrioli R, Fiaschi AI, Francini E, Pascucci A, Francini G. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer. Cancer Treat Rev. 2008; 34(8): 710-8[DOI][PubMed]
  • 43. Llaverias G, Danilo C, Wang Y, Witkiewicz AK, Daumer K, Lisanti MP, et al. A Western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer. Am J Pathol. 2010; 177(6): 3180-91[DOI][PubMed]
  • 44. Shirai T, Asamoto M, Takahashi S, Imaida K. Diet and prostate cancer. Toxicology. 2002; 181(2): 89-94
  • 45. Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, et al. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate. 2008; 68(1): 11-9[DOI][PubMed]
  • 46. Khan M A, Tania M, Zhang D, Chen H. Antioxidant enzymes and cancer. China J Cancer Res. 2010; 22(2): 87-92[DOI]
  • 47. Clinton SK. The dietary antioxidant network and prostate carcinoma. Cancer. 1999; 86(9): 1629-31[PubMed]
  • 48. Iynem AH, Alademir AZ, Obek C, Kural AR, Konukoglu D, Akcay T. The effect of prostate cancer and antiandrogenic therapy on lipid peroxidation and antioxidant systems. Int Urol Nephrol. 2004; 36(1): 57-62[PubMed]
  • 49. Peters U, Leitzmann MF, Chatterjee N, Wang Y, Albanes D, Gelmann EP, et al. Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2007; 16(5): 962-8[DOI][PubMed]
  • 50. Platz EA, Helzlsouer KJ. Selenium, zinc, and prostate cancer. Epidemiol Rev. 2001; 23(1): 93-101[PubMed]
  • 51. Redman C, Scott JA, Baines AT, Basye JL, Clark LC, Calley C, et al. Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett. 1998; 125(1-2): 103-10[PubMed]
  • 52. Meyer F, Galan P, Douville P, Bairati I, Kegle P, Bertrais S, et al. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer. 2005; 116(2): 182-6[DOI][PubMed]
  • 53. Dunn BK, Richmond ES, Minasian LM, Ryan AM, Ford LG. A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). Nutr Cancer. 2010; 62(7): 896-918[DOI][PubMed]
  • 54. Grant WB. The roles of ultraviolet-B irradiance, vitamin D, apolipoprotein E epsilon4, and diet in the risk of prostate cancer. Cancer Causes Control. 2011; 22(1): 157-8[DOI][PubMed]
  • 55. Kasperzyk JL, Fall K, Mucci LA, Hakansson N, Wolk A, Johansson JE, et al. One-carbon metabolism-related nutrients and prostate cancer survival. Am J Clin Nutr. 2009; 90(3): 561-9[DOI][PubMed]
  • 56. Position of the American Dietetic Association and Dietitians of Canada: Vegetarian diets. J Am Diet Assoc. 2003; 103(6): 748-65[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments